SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Schnereger who wrote (1049)12/12/1996 12:36:00 PM
From: John H. Farro   of 4342
 
As Rick C. and Robert Perissi have so eloquently stated elsewhere:

"GO PRLN, GO!"

I am surprised that the results cover only 9 weeks. I thought this was originally a 6 month study.

One of the subjects experienced severe allergic hypersensitivity.
Exactly what does that mean? Did the allergic symptoms disappear when he stopped taking the medicine? Could this type of hypersensitivity open the company up for lawsuits?

The one sentence I liked best in this report is the following:

"Overall, participants in the study were excited about the results and a majority of them wanted to continue after the completion of the
trial." This may mean subjects are likely to reorder the product, which is what Paul says is the key to PRLN's success.

Of course, if AndroVir only produces a median decrease in HIV-1 viral load of 38 percent and a median increase in CD4 cell counts of 31 percent then it can't compete with the other AIDS drugs that have been recently marketed. But it can act as a nice supplement to reinforce there strength. And a lot of people will be able to afford AndroVir at $1000/year for treatment who can't afford the other drugs. I'd say overall these results look promising.

Go PRLN, Go!

Linda, please pass my congratulations on to John.

Robin M.

How do others interpret this news?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News